Successful translational research depends of the flow of information not only from the laboratory to the clinic but also from the clinic to the laboratory and back. The objectives of the Clinical Core are: 1. To provide clinical support for specific Projects (2, 3, and 4) within the SPORE. Such support will include identification and acquisition of clinical samples from patients with specific stages of prostate cancer as well as obtaining consent for tissue donation post-mortem for the Tissue Acquisition at Necropsy program. In addition the Clinical Core will run the neoadjuvant chemotherapy trial and obtain extra prostate tissue to be snap frozen before chemotherapy and at radical prostatectomy. It will also conduct the proposed phase I/II trial of anti-sense clusterin for Project 3. 2. To establish a unified clinical database. The goal will be to bring established databases already in existence in different disciplines into a unified format that will permit entry of real-time patient data on all consenting patients with prostate cancer. This will permit rapid identification of specific populations of patients for clinical trials or other analyses. Methods for linking the clinical data to the specimen database will be established in collaboration with the Tissue and Statistical Cores. 3. To support a translational research infrastructure. Members of Core E will play an active role in the Translational Working Teams (TWT) which will meet every other month. The ultimate goal of these teams is to bring promising research findings into the clinic as quickly as possible. Core E will design and conduct clinical trials which grow out of TWT meetings. The multi-disciplinary, translational approach will also be used as a model to train fellows in clinical research, specifically in prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA097186-01
Application #
6671841
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-19
Project End
2007-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53
Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Plymate, Stephen R; Sharp, Adam; de Bono, Johann S (2018) Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA Oncol 4:1187-1188
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362
Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735

Showing the most recent 10 out of 400 publications